Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology. (PubMed, PLoS One) - Jan 18, 2025 - "Our integrative analysis suggested that levels of circulating PPP3CA; PPP3R1 had causal effects on SLE risk and served as potential treatment targets. Moreover, this study provides new evidence for Voclosporin as an SLE treatment through Mendelian randomization and Network pharmacology, and warrants further clinical investigation."
Journal • Observational data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • ICAM1 • PACERR • PPP3CA • PPP3R1 • PTGS2 • SIRT1
|
|
Shufen Liang; Tiewen Jia; Yanan Xu; Zelin Wang
|